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https://doi.org/10.1016/j.celrep.2021.109869SUMMARYThe dramatically expanding coronavirus disease 2019 (COVID-19) needsmultiple effective countermeasures.
Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19. Here, we charac-
terize several receptor binding domain (RBD)-specific Nbs isolated from an Nb library derived from an alpaca
immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S);
among them, three Nbs exhibit picomolar potency against SARS-CoV-2 live virus, pseudotyped viruses, and
circulating SARS-CoV-2 variants. To improve their efficacy, various configurations of Nbs are engineered.
Nb15-NbH-Nb15, a trimer constituted of three Nbs, is constructed to be bispecific for human serum albumin
(HSA) and RBD of SARS-CoV-2. Nb15-NbH-Nb15 exhibits single-digit ng/ml neutralization potency against the
wild-type and Delta variants of SARS-CoV-2 with a long half-life in vivo. In addition, we show that intranasal
administration of Nb15-NbH-Nb15 provides effective protection for both prophylactic and therapeutic pur-
poses against SARS-CoV-2 infection in transgenic hACE2 mice. Nb15-NbH-Nb15 is a potential candidate
for both the prevention and treatment of SARS-CoV-2 through respiratory administration.INTRODUCTION
As of February 1st, 2021, severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2) has caused more than 100 million
confirmed cases and over 2.2 million deaths globally. The
containment of the expanding coronavirus disease 2019
(COVID-19) pandemic needs multiple countermeasures. Pro-
phylactic vaccines have been recently approved (Dai and Gao,
2020), and a number of SARS-CoV-2-neutralizing monoclonal
antibodies (mAbs) that target the receptor binding domain
(RBD) of the spike protein (Baum et al., 2020; Ju et al., 2020;
Liu et al., 2020; Rogers et al., 2020; Shi et al., 2020) were identi-
fied, which could be developed as either therapeutic or prophy-
lactic agents.C
This is an open access article under the CC BY-NIn addition to conventional antibodies, camelids also
generate heavy-chain-only antibodies (HCAbs), constituting a
single variable domain (nanobody [Nb]) specific for binding an-
tigens (Hamers-Casterman et al., 1993). This single variable
domain, referred as a single-domain antibody, variable heavy-
chain domains of heavy-chain antibody (VHH), or Nb, has
higher affinity, thermal stability, and chemostability than most
antibodies (Jovcevska and Muyldermans, 2019; Steeland
et al., 2016) and can be constructed easily into multivalent for-
mats devoid of Fc, which will overcome potential deleterious
antibody-dependent enhancement (ADE) of infection observed
in some viral infections, including dengue virus, HIV, and SARS-
CoV (Luo et al., 2018; Taylor et al., 2015; Tirado and Yoon,
2003). Their favorable biophysical properties have led to theell Reports 37, 109869, October 19, 2021 ª 2021 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion, such as severe fever with thrombocytopenia syndrome vi-
rus (SFTSV) (Wu et al., 2020a) and respiratory syncytial virus
(RSV) (Cunningham et al., 2020; Detalle et al., 2015; Van Heeke
et al., 2017).
SARS-CoV-2 is transmitted by the upper respiratory tract
(Zhou et al., 2020), and an analysis of clinical specimens showed
that SARS-CoV-2 was detected with the highest viral copies in
multiple sites of the respiratory tract, whereas few viral copies
are in the blood (Wang et al., 2020). These data indicate that bio-
therapeutic agents directly delivered by the respiratory route to
the sites of infection would be an attractive alternative to sys-
temic routes of administration. Parenteral inoculation of a bio-
therapeutic antibody is a particularly ineffective way to deliver
drugs to the respiratory tract. Indeed, a study on mepolizumab
(anti-interleukin-5 mAb) demonstrated that only 0.2% of the
dose administered reached the lung by systemic administration
(Hart et al., 2001). In addition, the therapeutic effect of pulmonary
delivery of human immunoglobulins for controlling RSV in cotton
rats was shown to be 160 times more effective than that by the
parenteral administration (Prince et al., 1987). Thus, pulmonary
delivery may be superior to parenteral administration for the
treatment of respiratory tract infections.
A key requirement for pulmonary delivery is the stability of the
biologic product so that it endures the degrading environment,
and thus, the drugwill have to be formulated tomaintain its struc-
tural integrity and bioactivity through the upper respiratory tract
and the lungs. Nbs are delivered directly to the lungs by an
inhaler given their small size, simple and robust structure, high
thermal stability, and solubility. For instance, ALX-0171, a homo-
trimeric Nbs, is highly effective at reducing nasal and lung RSV
titers by the pulmonary administration of inhalation (Cunningham
et al., 2020; Detalle et al., 2015).
To date, several Nbs against SARS-CoV-2 were reported
for their in vitro activities; however, only few Nbs have
recently been evaluated in vivo (Dong et al., 2020; Hanke
et al., 2020; Huo et al., 2020; Nambulli et al., 2021; Pymm
et al., 2021; Schoof et al., 2020; Wu et al., 2020b; Xiang
et al., 2020). In the current report, anti-sera specific for
RBD were elicited by immunizing an alpaca with the SARS-
CoV-2 spike glycoprotein (S). Nbs specific for RBD were iso-
lated from a phage library displaying Nbs. We identified three
Nbs exhibiting potent neutralization activity against live virus
and a panel of SARS-CoV-2 pseudotyped viruses. To improve
the efficacy and stability, various configurations of Nbs were
engineered. Nb15-NbH-Nb15, a bispecific format constituted
of three Nbs, was constructed to be trivalent and bispecific
for the RBD of SARS-CoV-2 and human serum albumin
(HSA). This bispecific antibody exhibited potent inhibitory ac-
tivity against the wild type and variants of SARS-CoV-2,
including the currently circulating variants, such as the pre-
dominant mutant viruses in the United Kingdom and South
Africa with an N501Y mutation. In addition, we showed that
intranasal (i.n.) administration of Nb15-NbH-Nb15 provided
100% protection in both the prevention and treatment of
SARS-CoV-2 -infected transgenic hACE2 mice. Nb15-NbH-
Nb15 is a potential candidate for both the prevention and
treatment of SARS-CoV-2.2 Cell Reports 37, 109869, October 19, 2021RESULTS
Anti-sera response elicited by the S protein
One alpaca was immunized with the extracellular domain of the
SARS-CoV-2 spike protein (S1+S2 ECD, S) (Figure S1A).
Compared to the pre-immunized serum (blank serum), the anti-
serum after the third immunization exhibited specific serologic
activities against SARS-CoV-2 S and RBD proteins with binding
titers of 2.19 3 106 and 7.29 3 104, respectively (Figures S1B
and S1C). The immunized serum showed potent neutralization
activity against the pseudotyped SARS-CoV-2 with a half-
maximal neutralization dilution (ND50) of 9,600 (Figure S1D).
These data indicate that potent anti-serum specific for RBD
with robust neutralization against SARS-CoV-2 was induced in
the immunized alpaca.
Isolation of Nbs with potent neutralization activity
against SARS-CoV-2
To isolate monoclonal Nbs, a C9-Nb library, a phage library dis-
playing Nbs from the immunized alpaca, was constructed with a
size of 2.0 3 109, 100% sequence diversity, and 96% in-frame
rate as validated by PCR and sequencing (Figure S2A). Nbs spe-
cific for the SARS-CoV-2 S protein were isolated through three
rounds of biopanning on the C9-Nb phage library by the S pro-
tein. The panned library was analyzed by phage ELISA for bind-
ing with the S protein, and we found an incremental increase of
the optical density 450 (OD450) readout from 0.79 before enrich-
ment to 1.6, 2.4, and 2.8 after the first, second, and third rounds
of enrichment, respectively (Figure S2B), indicating successful
enrichment. To verify whether the enriched library contained
specific S-reactive phages, 40 and 46 clones were selected
from the libraries after the second and third rounds, respectively,
of enrichment for single-phage ELISA. The percentage of posi-
tive clones was 57.5% and 69.6% for the second and third
rounds, respectively (Figure S2C). Among these positive binders,
21 distinct Nb sequences were identified according to the
sequencing results (Table S1). For a further characterization,
these 21 Nbs were expressed in mammalian cells by fusing the
Nb genewith a human Fc1, whichwas cloned into the pCDNA3.4
vector to express the Nb-Fc antibody (named as Nb-Fc) (Fig-
ure S3A). ELISA results showed that all 21 Nb-Fcs reacted with
the S protein; among them, 14Nb-Fcs displayed specific binding
with the SARS-CoV-2 RBD protein (Figure S3B). These results
were validated by bio-layer interferometry (BLI), wherein 14
Nb-Fcs exhibited specific binding to RBD with dissociation con-
stant (KD) values ranging from 4.25 to 37.6 nM (Figures S3C and
S3D). A neutralization analysis showed potent inhibition of pseu-
dotyped SARS-CoV-2 by culture supernatants of RBD-specific
Nb15-Fc, Nb22-Fc, and Nb31-Fc (Figure S3E).
Epitope analysis of Nb-Fcs
The purified Nb15-Fc, Nb22-Fc, and Nb31-Fc exhibited dose-
dependent binding with the RBD protein by ELISA (Figure S4A).
In addition, Nb15-Fc, Nb22-Fc, and Nb31-Fc likely reacted with
the conformational structure, as their bindings with reduced
RBD protein were almost completely abolished (Figure S4B).
The kinetic binding of Nb15-Fc, Nb22-Fc, and Nb31-Fc with the
RBD protein ranged from a KD of 1.13 to 1.76 nM, indicating








Figure 1. Characterizing the potency and breadth of neutralization conferred by Nb-Fcs
(A and B) The neutralization potency of Nb-Fcs was detected based on an authentic SARS-CoV-2 plaque reduction neutralization test (A) and the pseudotyped
SARS-CoV-2 neutralization assay (B). SNB02 was taken as a negative isotype control antibody (Nb fused with human Fc1).
(legend continued on next page)
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which was substantiated by the superimposed ELISA binding
curves (Figure S4A). These three Nb-Fcs were next evaluated
for epitope specificity in a competition assay by BLI by using
the RBD protein as a capture antigen. The results revealed that
the pre-bound Nb-Fcs efficiently blocked the further binding of
the other twoNb-Fcs to theRBDprotein, suggesting that all three
Nb-Fcs likely recognize an overlapping epitope (Figures S5A–
S5C). Together, Nb15-Fc, Nb22-Fc, andNb31-Fc recognize a qua-
ternary and overlapping epitope on RBD with nanomolar
affinities.
Nb-Fcs exhibit potent neutralization against SARS-CoV-
2 and variants
The neutralizing activity of Nb15-Fc, Nb22-Fc, and Nb31-Fc
against SARS-CoV-2 live virus was investigated in Vero E6 cells.
All three Nb-Fcs exhibited potent neutralization activity with
the half maximal inhibitory concentration (IC50) values in the
range of 0.0033–0.0068 mg/ml (41.3-75 pM) and IC90 in the range
of 0.0156–0.0235 mg/ml (195–293.8 pM) (Figure 1A; Figures
S6A–S6E). The neutralizing potency was validated by the
SARS-CoV-2 pseudovirus neutralization assay with consistent
results, with IC50 values of 0.0008, 0.0018, and 0.0023 mg/ml
(10, 22.5, and 28.8 pM), respectively (Figure 1B; Table S2). The
IC50 values are comparable to those of the ultrapotent neutral-
izing antibodies or Nbs reported (Robbiani et al., 2020; Rogers
et al., 2020; Schoof et al., 2020; Xiang et al., 2020; Zost et al.,
2020). The cross neutralization of these Nbs against other coro-
naviruses was also evaluated in a pseudovirus assay, and the re-
sults showed that these three Nb-Fcs did not inhibit eitherMiddle
East Respiratory Syndrome (MERS)-CoV or SARS-CoV pseudo-
virus (Figures 1C and 1D) but inhibited 15 representative variants
of SARS-CoV-2 that are identified to represent over 7,000
distinct viral genomes (Baum et al., 2020). As expected, Nb15-
Fc, Nb22-Fc, and Nb31-Fc also inhibited the replication of
recently arising SARS-CoV-2 variants with a D614G mutation
with similar potency (Figures 1E–1G; Table S2). This evidence
demonstrates the neutralizing activity of the Nb-Fcs against mul-
tiple SARS-CoV-2 variants and suggests that the Nb-Fcs target
at a highly conserved epitope on the RBD protein. Taken
together, these three Nb-Fcs exhibited excellent neutralization
potency against the original and the representative variants of
SARS-CoV-2, whereas they did not inhibit MERS-CoV and
SARS-CoV infection. Given the overlapped epitope recognized
by the three Nb-Fcs, Nb15-Fc with the highest neutralization po-
tency was selected for further investigation.
Construction and characterization of multiple-valent
Nb15s
To improve potency, prolong in vivo half-life, and avoid potential
Fc-mediated ADE, a number of dimeric and trimeric configura-
tions of Nbs were engineered. Monomer (13 Nb15), homodimer(C–G) Nb-Fcs were tested for the neutralization against the pseudovirus infectio
variants identified from circulating viral sequenceswere tested to evaluate the neu
axis shows the ratio of IC50 of indicated SARS-CoV-2 variant/IC50 of SARS-CoV-2
an amino acid point mutation based on the wild type of SARS-CoV-2 are indicated
twice.
4 Cell Reports 37, 109869, October 19, 2021(23 Nb15), homotrimer (33 Nb15), and homotetramer (43 Nb15)
formats were constructed and analyzed by BLI. The binding of
these constructs to the RBD protein showed an increasing KD
ranging from 12 to <0.001 nM as the valence increased (Figures
2A and 2B). Multivalent formats of Nb15 were evaluated for
neutralization against pseudotyped SARS-CoV-2 infection
in vitro. Monomeric 1 3 Nb15 exhibited low inhibitory activity
with an IC50 of 307 ng/ml (2.3 nM), whereas the bi-, tri-, and tetra-
valent configurations exhibited higher neutralization potency
than the monomer but comparable potency among the multi-
mers with IC50 values of 2.8, 3.5, and 2.3 ng/ml (11, 9.0, and
4.3 pM), respectively (Figure 2C; Table 1), suggesting that
increasing valence does not confer improved anti-viral activity.
As such, 33Nb15was selected for further functional exploration.
Nb15-NbH-Nb15, heterotrimeric and bispecific for RBD
and HSA, exhibits potent neutralization against SARS-
CoV-2
In order to improve Nb15 efficacy and stability in vivo, we con-
structed bispecific Nbs consisting of one Nb specific for HSA
(NbH) developed by our lab and one or two Nb15s specific for
RBD with (G4S)3 as the linker between each Nb (Figure 3A) and
analyzed their binding and viral inhibitory activities. In addition
to the heterodimeric configuration of Nb-NbH that was previously
reported (Van Roy et al., 2015), various configurations of Nbs
were engineered as depicted in Figure 3A. An ELISA analysis
showed that all combinations containing Nb15 reacted with the
RBD protein; among them, heterotrimeric Nb15-Nb15-NbH,
NbH-Nb15-Nb15 , and Nb15-NbH-Nb15 exhibited better binding
with the RBD protein than heterodimeric Nb15-NbH and NbH-
Nb15 configurations (Figures 3A and 3B). Furthermore, Nb15-
NbH, NbH-Nb15-Nb15, and Nb15-NbH-Nb15 were the top HSA
binders as compared to other configurations (Figures 3A and
3C). Bispecific Nbs in various configurations were tested for the
inhibition of SARS-CoV-2 infection; among them, Nb15-NbH-
Nb15 exhibited themost potent neutralization of the pseudotyped
virus with an IC50 of 0.4 ng/ml (9.0 pM) (Figure 3D; Table 1). We
next compared Nb15-NbH-Nb15 with homotrimer Nbs (3 3
Nb15) or Nb-Fc for their binding and anti-viral activities and found
that 33 Nb15, Nb15-NbH-Nb15, and Nb15-Fc exhibited compara-
ble potency with IC50 values of 0.4, 0.4, and 0.9 ng/ml (9.0, 9.0,
and 11.3 pM), respectively (Figure 3E; Table 1).
Pharmacokinetics and delivery of Nb constructs
Given that 3 3 Nb15, Nb15-NbH-Nb15, and Nb15-Fc exhibited
comparable neutralization activity (Figure 3E), these three
constructs were evaluated for their in vivo pharmacokinetic
activity. The results showed that, when administrated by i.n.,
intraperitoneal (i.p.), or intravenous (i.v.) routes, 3 3 Nb15
was rapidly metabolized as compared to Nb15-Fc and Nb15-
NbH-Nb15 (Figures 4A–4C); therefore, 3 3 Nb15 was ruled
out for further analysis. To determine the tissue distributionn of SARS-CoV (C) and MERS-CoV (D). The pseudovirus of 15 SARS-CoV-2
tralization potency conferred byNb15-Fc (E), Nb22-Fc (F), andNb31-Fc (G). The y
wild-type (WT) conferred by Nb-Fcs. The names of SARS-CoV-2 variants with
. Data are represented as mean ± SEM. All experiments were repeated at least
A C
B
Figure 2. Characterization of Nb15s with multivalent or various formats
(A) The binding curve of multivalent Nb15s with RBD protein detected by BLI.
(B) The table summary of the binding of Nb15s with RBD protein tested by BLI.
(C) Multivalent Nb15s and various formats were evaluated for neutralization potency against pseudotyped SARS-CoV-2 infection.









1 3 Nb15 0.3074 ± 0.0237 0.5059 ± 0.0699 0.622 ± 0.0969
2 3 Nb15 0.0003 ± 0 0.0008 ± 0.0001 0.0011 ± 0.0001
3 3 Nb15 0.0004 ± 0 0.001 ± 0 0.0014 ± 0.0001
4 3 Nb15 0.0002 ± 0.0001 0.0008 ± 0.0001 0.0011 ± 0.0002
Nb15-NbH 0.5529 ± 0.0889 1.071 ± 0.1754 1.374 ± 0.2263
NbH-Nb15 0.1974 ± 0.004 0.3469 ± 0.0533 0.4344 ± 0.0822
Nb15-
Nb15-NbH
0.0251 ± 0.0058 0.0419 ± 0.0051 0.0517 ± 0.0047
NbH-
Nb15-Nb15
0.0008 ± 0.0001 0.0017 ± 0.0003 0.0022 ± 0.0004
Nb15-
NbH-Nb15
0.0004 ± 0 0.0009 ± 0 0.0013 ± 0
Nb15-Fc 0.0009 ± 0.0001 0.0019 ± 0.0001 0.0025 ± 0.0002
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YF750) were administered by i.n., i.p., or i.v. routes in mouse
model. The results revealed that the fluorescence in trachea
could be detected only when Nb15-NbH-Nb15-YF750 was
administered i.n. Furthermore, the fluorescence intensity was
higher in lungs when Nb15-NbH-Nb15-YF750 was administered
i.n. (6.9 3 1010 ph/s) than that when administered i.p. or i.v.
(1.4 3 1010 and 4.3 3 1010 ph/s, respectively) (Figures 4D
and 4E). In addition, the results also showed that Nb15-NbH-
Nb15 could reach lungs and was sustained for more than
168 h (7 days) when administrated i.n.; in contrast, the fluores-
cence could only be detected between 1 and 2 h after i.p. infu-
sion (Figures 4F and 4G). These results suggest that i.n.
administration of Nb15-NbH-Nb15 will be a favorable route for
the antibody to reach the nasopharynx and lungs where
SARS-CoV-2 replicates. Therefore, to avoid the potential
ADE associated by Fc in the Nb-Fc, we selected Nb15-NbH-
Nb15 for further efficacy evaluation in vivo.
In vitro characterization of Nb15-NbH-Nb15
Nb15-NbH-Nb15 was further characterized in vitro. Nb15-NbH-
Nb15 exhibited specific binding to RBD and HSA with KD values
of 0.54 and 7.7 nM, respectively (Figures 5A and 5B). In addi-
tion, Nb15-NbH-Nb15 also showed specific binding with murine
serum albumin (MSA) with KD values of 14.5 nM (Figure S7),
indicating that mice can be used as an animal model to inves-
tigate the half-life of Nb15-NbH-Nb15. Furthermore, Nb15-NbH-
Nb15 exhibited sub-ng/ml (pM) potency against both the wild
type (WHU01) and 18 out of 19 currently circulating SARS-
CoV-2 mutant variants tested (Figure 5C; Table S2). Impor-
tantly, Nb15-NbH-Nb15 showed comparable potency against
the pseudotyped SARS-CoV-2 variants with D614G and
N501Y mutations that circulate predominantly in the UnitedKingdom and South Africa. Moreover, Nb15-NbH-Nb15 ex-
hibited neutralization against pseudotyped variants of the wild
type, Alpha (N501Y), Epsilon (L452R), and Delta (L452R and
T478K) with IC50 values of 0.4 ng/ml, 0.26 ng/ml, 88.95 ng/
ml, and 5.16 ng/ml (9.0, 5.9, 2001, and 116 pM), respectively.
However, it failed to neutralize Gamma (E484K and K417T),
Beta (E484K and K417N), and other circulating variants (Fig-
ure 5D). Nb15-NbH-Nb15 also showed excellent thermal stability
by retaining 100% and 83% activities even at 70C and 80C
for 1 h, respectively (Figures 5E and 5F; Table S3). Further-
more, Nb15-NbH-Nb15 retained 100% activity after aerosoliza-
tion, indicating the potential application as a nebulized drug






Figure 3. Design and characterization of
bispecific Nbs
(A) Various Nbs at 37 mg/ml binding to RBD, and
HSA protein identified by ELISA.
(B and C) The binding curve of Nbs interacting with
RBD protein (B) and HSA protein (C) identified by
ELISA.
(D) The neutralizing potency of bispecific Nbs
against SARS-CoV-2 pseudovirus measured by
neutralization assay.
(E) The neutralizing potency of Nb15-Fc, 33 Nb15,
and Nb15-NbH-Nb15 against SARS-CoV-2 pseu-
dovirus infection measured by neutralization
assay.
Data are represented as mean ± SEM. All experi-
ments were repeated at least twice.
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To evaluate the efficacy of Nb15-NbH-Nb15 in vivo, hACE2
transgenic mice were challenged with 1 3 105 PFU SARS-
CoV-2 (Strain IVCAS 6.7512; Zhou et al., 2020), and Nb15-NbH-
Nb15 was administrated i.n. either before or after viral challenge
for prophylactic or therapeutic efficacy (Figure 6A). Viral RNA
was detected in the lungs of control mice (6.28 3 105 copies/
mg on average in SARS-CoV-2 group, n = 5) and the isotype-
treated control mice (7.83 104 copies/mg on average in isotype
group, n = 3). For the prophylactic group, no viral RNA or infected
cells were detected in 100% (5/5) of the mice when 250-mg
(average of 10 mg/kg) Nb15-NbH-Nb15 was administrated i.n.
24 h before SARS-CoV-2 infection (Nb15-NbH-Nb15 24h group,
n = 5), as evidenced by real-time PCR and immunofluorescence
staining (Figures 6B–6D). A total of 100% of mice were also
completely protected when 250-mg Nb15-NbH-Nb15 as adminis-
trated i.n. 1 h postinfection, as no viral RNA and infected cells
were detected in all infected mice (Nb15-NbH-Nb15 1-h group,
n = 5) (Figures 6B–6D). Significantly lower SARS-CoV-2 RNA
copies (9.98 3 103 copies/mg on average) were detected in
the lungs of the mice treated with Nb15-NbH-Nb15 i.n. 24 h post-
infection (Nb15-NbH-Nb15 24 h group, n = 5) than those in the
control mice (6.28 3 105 copies/mg on average in SARS-CoV-
2 group and 7.8 3 104 copies/mg in isotype control) (Figures
6B–6D). Nb15-Fc inhibited viral replication and reduced the viral
copy number (average of 7.59 3 103 copies/mg in Nb15-Fc 1-h6 Cell Reports 37, 109869, October 19, 2021group, n = 5) but failed to provide com-
plete protection under the same condi-
tions as Nb15-NbH-Nb15 (Figures 6B–
6D). Furthermore, a histopathological
analysis of lung tissues showed that
SARS-CoV-2 challenge induced severe
lung lesions, as shown by the infiltration
of inflammatory cells and thickened alve-
olar septa (Figure 6D). In contrast, the
lungs of the mice receiving Nb15-NbH-
Nb15 or Nb15-Fc treatment showed no
apparent pathological changes (Fig-
ure 6D). Together, Nb15-NbH-Nb15 at an
average of 10 mg/kg administrated i.n.
24 h before or 1 h after challenge pro-vided complete protection against SARS-CoV-2 infection and
significantly inhibited SARS-CoV-2 replication when the anti-
body was administrated 24 h postinfection. Nb15-Fc used at an
average of 10 mg/kg administrated i.n. 1 h after challenge signif-
icantly reduced viral load but failed to provide complete protec-
tion. We noted that those mice receiving Nb15s treatment
showed less weight loss than the control mice but did not
achieve a statistical difference (Figures 6E and 6F). These results
indicate that Nb15-NbH-Nb15, when used early during infection,
conferred a higher protection efficacy than that used at a later
time point. In summary, the Nb15-NbH-Nb15 configuration
administered i.n. was superior to Nb15-Fc and exhibited both
prophylactic and therapeutic efficacy against SARS-CoV-2
challenge.
DISCUSSION
In this study, three potent neutralizing Nb-Fcs were isolated from
a phage display platform derived from an alpaca immunized with
the SARS-CoV-2 S protein. These three RBD-specific Nb-Fcs
exhibited potent inhibitory activities against 15 mutant variants
of pseudotyped SARS-CoV-2 with IC50 values in the range of
0.5-2.8 ng/ml (Figures 1E–1G; Table S2). The IC50 values are
comparable to those of the most potent neutralizing antibodies
or Nbs reported (Robbiani et al., 2020; Rogers et al., 2020;
Schoof et al., 2020; Xiang et al., 2020; Zost et al., 2020). These
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Figure 5. Functional characterization of
Nb15-NbH-Nb15
(A and B) Kinetic binding curve of Nb15-NbH-Nb15
at the concentrations 300 nM, 100 nM, 33.3 nM,
11.1 nM, 3.7 nM, and 1.2 nMwith RBD (A) and HSA
(B) by BLI. Binding curves are colored black, and
the fit of the data to a 1:1 binding model is colored
red.
(C) The neutralization curve of Nb15-NbH-Nb15 in-
hibiting SARS-CoV-2 pseudovirus and its variants
with amino acid point mutation as indicated. WT,
wild-type SARS-CoV-2 pseudovirus of 2019-
nCoV WHU01 (accession ID: MN988668.1).
(D) The neutralization curve of Nb15-NbH-Nb15 in-
hibiting SARS-CoV-2 pseudovirus of circulating
variants. WTwas indicated as in (C). Alpha, B.1.1.7
variant reported in United Kingdom; Beta, B.1.351
variant reported in S. Africa; Gamma, P.1 variant
reported in Brazil; Epsilon, B.1.429 variant re-
ported in California; Delta, B.1.617.2 variant re-
ported in India; Eta, B.1.525 variant reported in
UK; Iota, B.1.526 variant reported in New York;
Kappa, B.1.617.1 variant reported in India.
(E) Binding curve of RBD with Nb15-NbH-Nb15 at
the concentration of 133 nM (5 mg/ml) before (no
treatment, WT) or after aerosolization (Aero) or
after treatment at the indicated temperature,
including 37C, 50C, 60C, 70C, 80C, and 90C
for 1 h. Binding curves are colored black, and the
fit of the data to a 1:1 binding model is colored as
indicated.
(F) Snapshot of the relative binding response of the
highest binding response at the indicated condi-
tion/the highest response of RBD with Nb15-NbH-
Nb15 in the no-treatment condition (WT). The
relative binding of WT was normalized as 100%.
Data are represented as mean ± SEM. All experi-
ments were repeated at least twice.
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OPEN ACCESS15 representative variants of SARS-CoV-2 are identified to
represent over 7,000 distinct viral genomes (Baum et al., 2020).
As expected, recently arising variants with a D614G mutation
were also sensitive to the neutralization by Nb15-Fc, Nb22-Fc,
and Nb31-Fc with similar sensitivity (Figures 1E–1G; Table S2).
This evidence demonstrates the neutralizing activity of theseFigure 4. Pharmacokinetics of Nb15s in vivo
(A–C)Bioavailability andT1/2 (half-life) ofNb15s inBALB/cmice.Nb15 variantswere in
kgmice) (A), intraperitoneally (i.p.) administered intomice (n=3, female) at400mg (av
female) at 400 mg (average of 20mg/kgmice) (C). Serum concentrations of the Nbs
follows: Nb15-Fc (red), Nb15-NbH-Nb15 (orange), and 33 Nb15 (cyan). Cmax, maxim
(D) Spatial distribution of Nb15-NbH-Nb15YF750 1 h after infusion into mice (n = 3
system. The middle figure in the red dashed line shows the dissected image of
dissected mice that were imaged immediately after sacrifice. Tr, trachea; Lu, lu
kidneys; B, bladder.
(E) The fluorescence intensity (ph/s) summary of each organ in (D) was quantified
(F) Pharmacokinetics of Nb15-NbH-Nb15-YF150 by i.n. administration at the indicat
fluorescence intensity in various organs labeled as in (D). The blue dashed line figu
arrows.
(G) Nude mice (n = 3–6) were administered with Nb15-NbH-Nb15-YF750 by the i.n
yellow dashed line circle of M02 in (F) was measured at the indicated time point.
8 Cell Reports 37, 109869, October 19, 2021Nbs against multiple SARS-CoV-2 variants and suggests that
the Nb-Fcs target at a highly conserved epitope on the RBD
protein.
To improve potency, prolong in vivohalf-life, and avoid potential
Fc-mediated ADE, NbH specific for HSA and MSA was used to
construct a trimeric Nb15 (Nb15-NbH-Nb15) for SARS-CoV-2, andtranasally (i.n.) administered intomice (n=3, female) at 200mg (average of 10mg/
erageof20mg/kgmice) (B), and intravascularly (i.v.) administered intomice (n=3,
were determined at indicated time points by ELISA. Nb15 variants are colored as
um observed plasma concentration. Data are represented as mean ± SEM.
in each group) by i.n., i.p., and i.v. routes was detected by a NightOwl LB 983
the left mouse in the red dashed line. The right figure shows the organs from
ng; H, heart; Li, liver; Sp, spleen; St, stomach; I, large and small intestine; Ki,
and presented as the mean ± SEM.
ed time point. Micewere sacrificed at the indicated time point for the analysis of
re shows the enlarged image of the individual figure indicated by corresponding
. or i.p. route. The fluorescence intensity at the lung location as shown in the
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OPEN ACCESSthe resulting Nb15-NbH-Nb15 exhibited the highest neutralization
potency with the IC50 value of 0.4 ng/ml among other configura-
tions, including Nb15-NbH, a configuration reported earlier (Van
Roy et al., 2015). Interestingly, we found that Nb15-NbH and
NbH-Nb15 with the same components exhibited distinct neutrali-
zation potencies with IC50 values of 552.3 ng/ml and 197.4 ng/
ml, respectively. In addition, NbH-Nb15-Nb15 and Nb15-Nb15-NbH
also displayed distinct neutralization potencies with IC50 values
of 25.1 ng/ml and 8 ng/ml, respectively (Figure 3D; Table 1), indi-
cating that the Nb configuration has an effect on the neutralizing
activity. In addition, the heterotrimeric bispecific configuration is
superior to the bispecific heterodimer. We also noted that the bi-
, tri-, and tetravalent configurations exhibitedcomparablepotency
with IC50 values of 2.8, 3.5, and 2.3 ng/ml (11, 9.0, and 4.3 pM),
respectively. The neutralizing potency did not correspond to the
valence increase when there are two or more than two Nb15s,
althoughmonomeric 13Nb15 had amuch lower inhibitory activity
(Figure 2C; Table 1). We noted that Nb15-NbH-Nb15 shows higher
potency than NbH-Nb15-Nb15, Nb15-Nb15-NbH, and all the homo-
multimers, suggesting that the position of NbH plays important
roles in neutralization activity. We speculate that in Nb15-NbH-
Nb15, NbHmay spaceout the twoNb15s toeither avoid cross inter-
eference with each other or allow better binding of the trimeric Nb
to S proteins on the viral particle. Furthermore, Nb15-NbH-Nb15
displayed comparable neutralizing potency as those of Nb15-Fc
and 3 3 Nb15 and higher neutralization potency and longer half-
life than 33 Nb15 in vivowhen delivered via i.n., i.p. or i.v. routes.
Altogether,Nb15-NbH-Nb15wasestablishedasapotentially prom-
ising construct, suggesting a format of nanobodieswith improved
potency and half-life in vivo.
Importantly, Nb15-NbH-Nb15 exhibited neutralizing activities
against 18 out of 19 pseudotyped SARS-CoV-2 variants except
the E484K mutant variant that we tested. Moreover, Nb15-NbH-
Nb15 exhibited neutralization against pseudotyped variants of
wild type (Wuhan-Hu-01), Alpha (N501Y, B1.1.7 variant, United
Kingdom), Epsilon (L452R, B1.429 variant, California), and Delta
(L452R and T478K, B.1.617.2 variant, India), which has become
predominant and contributed to the current wave of infection in
manycountries.Deltahasbeendesignatedasavariantof concern
(VOC) and is believed to be 60%more transmissible than variant
Alpha (Planas et al., 2021). SomemAbs, including bamlavinimab,
lost binding to the Spike and no longer neutralized variant Delta
(Planas et al., 2021). Nb15-NbH-Nb15 exhibited potent neutraliza-
tion against variant Delta (IC50 values of 5.16 ng/ml) with aboutFigure 6. The efficacy of Nb15s evaluated in hACE2 transgenic mice ch
(A) Experimental schedule of Nb15s in the prevention and treatment of SARS-Co
treatments.
(B) Viral loads in lungs among 7 groups weremeasured by qRT-PCR. The name of
one mouse. The limit of detection was 3,160 copies/mg referenced to blank con
(C) Sections of lungs were analyzed by immunofluorescence staining by using a
(40,6-diamidino-2-phenylindole) for nuclei in blue, respectively. The fluorescence
which was calculated by ImageJ software.
(D) Representative sections of lung in (C) were visualized under the320 objective
cells indicated by corresponding arrows at the indicated scale bar as 10 mm. H&E
indicated scale bar as 100 mm.
(E) Body weights of mice among the above 7 groups were recorded. Each line re
(F) Snapshot of body weight on 3 days post infection in (E) was plotted. Data are
treatment group with the SARS-CoV-2 control group. ns, no significance; *p < 0.05
SEM. All experiments of (B) and (C) were repeated twice.
10 Cell Reports 37, 109869, October 19, 202120-fold less potent neutralization against Alpha (IC50 values of
0.26 ng/ml) (Figure 5D). However, it failed to neutralize P.1
(E484K and K417T, Gamma, Brazil), B1.351 (E484K and K417N,
Beta, South Africa), B.1.617.1 (L452R and E484Q, India), and
other circulating variants (Figure 5D), suggesting a E484K/Q
mutation variant could be resistant to the neutralization of Nb15-
NbH-Nb15.
Although several neutralizing antibodies against SARS-CoV-2
are in various stages of clinical trials or have been approved as
an emergency therapy, most of these antibodies are of limited ef-
ficacy. SARS-CoV-2 is present mainly in the nasopharynx and
lungs (Gallo et al., 2020; Higgins et al., 2020). Differing from
many previously reported therapies with a systemic delivery
route, Nb15-NbH-Nb15 was delivered to the site of infection.
Direct administration to the airways is likely to provide faster
and more robust antiviral activity in the respiratory tract, where
the virus gains entry and replicates (Cunningham et al., 2020;
Higgins et al., 2020), as i.n. delivery has been shown to result
in fast and efficient drug delivery to the main site of SARS-
CoV-2 infection, i.e., the upper and lower respiratory tract
(Higgins et al., 2020). Indeed, the therapeutic effect of topical
administration of ALX-0171 displayed promising results in
reducing the RSV viral load (Cunningham et al., 2020; Detalle
et al., 2015). The current study demonstrated the in vivo efficacy
of Nbs against SARS-CoV-2 infection by i.n. delivery.
In summary, compared to the configurations of Nb-NbH, Nb-
Fc, and Nb homotrimer, a potential promising construct of
Nb15-NbH-Nb15 exhibited a higher neutralization activity and
longer half-life in vivo. Our results provide a strategy for the con-
struction of multivalent Nbs with improved potency and half-life
in vivo. Nb15-NbH-Nb15 exhibited highly potent antiviral activity
against a large panel of SARS-CoV-2 clinical variants except
E484K/Q mutants. Furthermore, direct delivery of Nb15-NbH-
Nb15 to the airways/lungs by the i.n. route proved an effective
mode of drug delivery, and the outstanding thermal stability of
Nb15-NbH-Nb15 is an additional advantage. We suggest that res-
piratory delivery of Nb15-NbH-Nb15 is a promising route for the
prevention and treatment of SARS-CoV-2 infection and thus
warrants further clinical evaluation by i.n. delivery.
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OPEN ACCESSSTAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-human IgG conjugated with an IRDye 800CW Rockland Cat#926-32232
Anti-rabbit IgG conjugated with an IRDye 800CW Rockland Cat#925-32211
Goat anti-llama IgG (H+L) secondary
antibody with HRP
Novus Cat# NB7242
Anti-M13 bacteriophage antibody with HRP Sino Biological Cat#11973-MM05T-H







Nucleocapsid Antibody, Mouse mAb
Sino Biological Cat#40143-MM05
SNB02 Y-Clone Cat#YL2018-003
Nanobody against HSA (NbH) Abrev Cat#AR2020-010
Bacterial and virus strains
TG1 bacteria Y-Clone N/A
M13KO7 helper phage Invitrogen Cat#18311019
SARS-CoV-2 live virus of Beta/Shenzhen/SZTH-




SARS-CoV-2 pseudovirus and its variants This Paper N/A
SARS-CoV pseudovirus This Paper N/A
Mers-CoV Pseudovirus This Paper N/A
SARS-CoV-2 live virus for animal study Wuhan Institute of Virology IVCAS 6.7512
Biological samples
Nb Phage library This Paper C9-Nb-lib




SARS-CoV-2 RBD protein Sino Biological Cat#40592-V08H
Freund’s complete adjuvant Sigma Cat#F5881-10ML
Freund’s incomplete adjuvant Sigma Cat#F5506-10M
3,30,5,50-Tetramethylbenzidine Sigma Cat#54827-17-7
Ficoll-Paque Plus GE Cat#17-1140-02
TRIzol reagent Life Technologies Cat#15-596-018
KPL TrueBlue Peroxidase Substrates SeraCare Life Sciences Inc. Cat#5510-0030
10% neutral buffered formalin Sigma Cat# Z2902
Far infrared dye YF750 SE US EVERBRIGHT INC YS0056
Critical commercial assays
Anti-human Fc (AHC) biosensors Fortebio Cat#18-5060
AR2G biosensor Fortebio Cat#18-5092
Amino coupling kit Fortebio Cat#18-5095
RT-PCR Prime Script Kit Takara Cat#PR005B
Experimental models: Cell lines
HEK293T-ACE2 cells Yeasen Biotech Cat# 41107ES0
Huh7 cells ATCC CCL-185
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
293T cells ATCC CRL-3216
293-F cells Thermo Fisher Scientific R79007
Experimental models: Organisms/strains
Transgenic hACE2 mice (C57BL/6J) GemPharmatech Cat T037630
Alpaca Y-Clone AR-0019
BALB/c Qing Long Shan
Animal Center
Qls02-0202




TaqMan probe (50-FAM CAGGT
GGAACCTCATCAGGAGATGC MGB-30)
This paper N/A
Primer of orf1ab gene of SARS-CoV-2 Forward:
(50- GTGARATGGTCATGTGTGGCGG 30 0)
This paper N/A




pCDNA3.1-S encoding spike protein
of variant coronavirus
This paper N/A
pCDNA3.4 eukaryotic expression vector Invitrogen Cat#A14697





phV1 phagemid plasmid Y-Clone N/A
pcDNA3.4-Nbs This paper N/A
Software and algorithms
GraphPad Prism 8.01 GraphPad Software Inc. https://www.graphpad.com/scientific-
software/prism/; RRID:SCR_002798
ImageJ https://imagej.nih.gov/ij/ https://imagej.nih.gov/ij/; RRID: SCR_001935
Indigo imaging software Berthold https://www.berthold.com/en/
bioanalytic/products/in-vivo-
imaging-systems/nightowl-lb983/
OriginPro 8.5 software OriginLab https://www.originlab.com/;
RRID:SCR_014212
Others
96-well plates Corning Cat# 9018
Protein G Thermo Fisher Scientific Cat# 20399
Ni-NTA Thermo Fisher Scientific Cat#R901100
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Alpaca used in the immunization
An alpaca (Female, 2-3 years old, cat.# AR-0019) was purchased from Xuzhou Animal Center (Xuzhou, China). Animal experiments
were done by veterinarian with the authorization of animal operation and in accordance with the China law for animal protection.
hACE2 mice in the evaluating efficacy of Nbs in vivo.
A total of 31 8-week-old male transgenic hACE2 mice (C57BL/6J) (cat.# T037630) were purchased from GemPharmatech Co., Ltd.
(Nanjing, China). All of the hACE2 mice were handled in Biosafety Level 3 animal facilities in accordance with the recommendations
for care and use of the Institutional ReviewBoard ofWuhan Institute of Virology of the Chinese Academy of Sciences (Ethics Number:
WIVA11202003).
BALB/c mice
BALB/c (6-8 weeks of age, Female, cat.# Qls02-0202) was purchased from Qing Long Shan Animal Center (Nanjing, China). The
BALB/cmice were kept in ventilated cages and given access to standard pellet feed andwater ad libitum following Nanjing University
Laboratory Animal center’s standard operational procedures.
Nude mice in spatial distribution of Nbs in vivo
Nudemice (18-22 g, female, Qls03-0102) were purchased fromQing Long Shan Animal Center (Nanjing, China). The nude mice were
kept in ventilated cages and given access to standard pellet feed and water ad libitum following Nanjing University Laboratory Animal
center’s standard operational procedures.
Cell lines
293T cells (ATCC), HEK293T-ACE2 cells (Cat# 41107ES0, Yeasen Biotech) and Huh7 cells (ATCC) were cultured in Dulbecco’sModi-
fied EagleMedium (DMEM) (Thermo Fisher Scientific) containing 10%Fetal bovine serum, 100 U/mL penicillin and 2mML-glutamine
and were incubated at 37C in 5% CO2 setting. 293-F cells (Thermo Fisher Scientific) were cultured in Expi293TM Expression Me-
dium and were incubated in a 37C incubator and 8% CO2 setting on an orbital shaker platform at 130 rpm according to the man-
ufacturer’s instructions.
Study approval
The study and the protocol for this research were approved by the Center for Public Health Research, Medical School, Nanjing Uni-
versity. All animal experimental procedures without infection were approved by the Committee on the Use of Live Animals by the
Ethics Committee of Nanjing University. All of the animals infected by SARS-CoV-2 were handled in Biosafety Level 3 animal facilities
in accordance with the recommendations for care and use of the Institutional Review Board of Wuhan Institute of Virology of the Chi-
nese Academy of Sciences (Ethics Number: WIVA11202003). All the authors declare their compliance with publishing ethics.
METHOD DETAILS
SDS-PAGE and western blotting (WB)
The purified protein or antibody was separated by electrophoresis in a 7.5%–12% polyacrylamide gel. The separated protein or
antibody was revealed either using Coomassie blue or transferred to PVDF membrane for WB analysis under reducing or non-
reducing conditions with b-mercaptoethanol. The membrane was first blocked and then incubated overnight at 4C or 37C for
one hour with diluted plasma or antibody, followed by incubation with the secondary antibody of either anti-human IgG or anti-
rabbit IgG conjugated with an IRDye 800CW (cat.# 926-32232, Rockland). Protein bands were visualized using the Odyssey Image
System (Li-COR).
ELISA analysis
Anti-sera titer and antibody characterization or antibody quantification in vivo were examined by ELISA as reported in our previ-
ously published method (Wu et al., 2019) with modifications. In brief, the protein was coated to high protein-binding ELISA plates
(Corning) at a concentration of 0.5 mg/ml, 100 mL per well at 37C for 2 hours (h) or 4C overnight. After washing, blocking buffer
with 5% non-fat milk in PBS was added and incubated at 37C for 1 h. After washing 2-4 times, 100 mL serially diluted anti-serum
or purified antibody was added and incubated at 37C for 1.5 h. Following washing, goat anti-llama IgG (H+L) secondary antibody
with HRP (Novus, cat.# NB7242, 1:10000 dilution) was added and incubated at 37C for 1 h. Accordingly, 3,30,5,50-Tetramethyl-
benzidine (TMB, Sigma) substrate was added at 37C for 10 minutes (min); and the reaction was stopped by adding 10 mL 0.2 M
H2SO4. The optical densities at 450 nm were measured using the Infinite 200 (Tecan, Ramsey, MN, USA). Antibody titers were
defined as the highest dilution when the diluted serum produced at least 2.1-fold optical density readout as compared to the con-
trol serum sample at the same dilution.Cell Reports 37, 109869, October 19, 2021 e3
Please cite this article in press as: Wu et al., A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal admin-




250 mg the extracellular domain of SARS-CoV-2 spike protein fused with His tag (S1+S2 ECD, S, cat.# 40589-V08B1, Sino Biological)
was emulsified with 250 mL Freund’s complete adjuvant (F5881-10ML, Sigma) to immunize an alpaca (Female, 2-3 years old, Y-
Clone, China). On day 14 and 28, the alpaca was boosted twice with 250 mg S protein in 250 mL Freund’s incomplete adjuvant
(F5506-10ML, Sigma). One week following the 2nd immunization, we collected the blood samples to measure anti-serum titer.
One week after the 3rd immunization, 100 mL of blood was collected to measure anti-serum titer and construct a phage library dis-
playing Nb.
Construction of a phage library displaying Nbs
Nb phage library was constructed following our previously published method with some modifications (Wu et al., 2020a). In brief,
PBMCs were isolated from 100 mL blood of immunized alpaca using a lymphocyte separation solution (cat.# 17-1140-02, Ficoll-Pa-
que Plus, GE). RNAwas extracted and reverse transcribed into cDNA by oligo (dT) and random hexamers as primers using the TRIzol
kit (cat.# 15596018, Life Technologies), followingmanufacturer’s instruction. The alpaca Nb gene was amplified with the combination
of primers and cloned into phV1 phagemid plasmid (Y-Clone, Ltd., China) to transform TG1 bacteria.
Panning Nb phage library and phage ELISA
Affinity selection for S-binding recombinant phages was performed as previously reported with the following modifications (Jähni-
chen et al., 2010). The Nb-phagemid-transformed bacteria were rescued with M13KO7 helper phage (cat.# 18311019, Invitrogen),
and precipitated with PEG/NaCl. The phage Nb antibody library was enriched three times with 50 mg/ml of S protein. The enriched
phage was eluted, transformed, and selected for the monoclonal phage to be evaluated by phage ELISA.
Phage ELISA
200 ng S or RBD protein in coating buffer (pH 9.6) was used to coat 96-well plates (cat.# 9018, Corning) at 4C overnight. After
washing, the plates were blocked with blocking buffer (3% BSA in PBST) for 1 h at 37C, and then incubated with library
phages or single clone phage in bacterial supernatant at 4C for 1.5 h. After washing, an anti-M13 bacteriophage antibody with
HRP (1:10000 dilution, cat.# 11973-MM05T-H, Sino Biological) was added and incubated at 37C for 1 h. Accordingly, TMB substra-
te(Sigma) was added at 37C for 10 min; 10 mL 0.2 M H2SO4 was added to stop the reaction. Optical densities were measured at
450 nm using the Infinite 200 (Tecan, Ramsey, MN, USA). Clones with readout at 450 nm > 0.5 were sequenced.
Expression and purification of Nbs with different formats
To facilitate the purification and prolong the half-life of the Nb antibody, the Fc1 gene (CH2-CH3) of the human monoclonal antibody
was fused with the Nb gene (Nb-Fc), as our previously published method (Wu et al., 2020a). In addition, to improve the activity of Nb,
we constructed Nbs with various configurations wherein (GGGGS)3 linkers were introduced between Nbs in dimeric and trimeric
forms. Nanobody specific to HSA, NbH (Table S1, Abrev biotechnology, China), was developed from an alpaca receiving the immu-
nization of HSA. To facilitate protein purification, a 6xHis-tag was fused to the N terminus of the Nbs ofmonomeric, dimeric or trimeric
configuration. The Nbs with different configurations were finally cloned into the pcDNA3.4 eukaryotic expression vector (Invitrogen),
which were transfected into 293F cells to produce Nbs with different configurations. Nb fused with Fc, or His tag was purified using
Protein G (cat.# 20399, Thermo Scientific) and Ni-NTA (cat.# R901100, Thermo Fisher Scientific), respectively.
Neutralization activity of Nbs against pseudovirus
Pseudovirus neutralization assay was performed as previously described with the following modifications (Ju et al., 2020). SARS-
CoV-2, SARS-CoV, and MERS-CoV pseudoviruses were produced by co-transfection of pNL4-3.Luc.R-E-, an HIV-1 NL4-3 lucif-
erase reporter vector that contains defective Nef, Env and Vpr (HIV AIDS Reagent Program), and pCDNA3.1 (Invitrogen) expression
vectors encoding the respective spike proteins (GenBank: MN988668.1 for SARS-CoV-2, AAP13567.1 for SARS-CoV, AFS88936.1
forMERS-CoV) into 293T cells (ATCC). Pseudovirus containing supernatants were collected after 48 h, and viral titers weremeasured
by luciferase assay in relative light units (Bright-Glo Luciferase Assay Vector System, PromegaBiosciences). S genes of SARS-CoV-2
variants with indicated mutations based on the human codon optimized S gene (GenBank: MN988668.1) were synthesized, and the
corresponding pseudoviruses were produced following above protocol. For neutralization assay, SNB02 (Nb-Fc) against SFTSV (Wu
et al., 2020a) served as a control. Neutralization assays were performed by incubating pseudoviruses with serial dilutions of purified
Nbs or serum at 37C for 1 h. HEK293T-ACE2 cells (cat.# 41107ES03, Yeasen Biotech Co., Ltd. China) for SARS-CoV-2 and SARS-
CoV, Huh7 cells (ATCC) for MERS-CoV (approximately 1.53 104 per well) were then added in duplicate to the virus-antibodymixture.
Half-maximal inhibitory dilution (ND50) of the evaluated sera or half-maximal inhibitory concentrations (IC50) of the evaluated Nbs
were determined by luciferase activity 48 h after exposure to virus-antibody mixture, and analyzed by GraphPad Prism 8.01 (Graph-
Pad Software Inc.).
Neutralization activity of Nbs against live SARS-CoV-2
SARS-CoV-2 focus reduction neutralization test was performed in a certified Biosafety Level 3 laboratory, as previously described
with the following modifications (Ju et al., 2020). Briefly, a clinical isolate (Beta/Shenzhen/SZTH-003/2020, EPI_ISL_406594 ate4 Cell Reports 37, 109869, October 19, 2021
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Nbs weremixed with 75 mL of SARS-CoV-2 (83 103 focus forming unit/ml, FFU/ml) in 96-well microwell plates and incubated at 37C
for 1 h. The mixtures were then transferred to 96-well plates seeded with Vero E6 cells and incubated at 37C for 1 h. Next, the in-
oculums were removed prior to the addition of the overlay media (100 mL MEM containing 1.6% carboxymethylcellulose, CMC) and
the plates were then incubated at 37C for 24 h. Cells were fixedwith 4%paraformaldehyde solution for 30min, and then the overlays
were removed. Cells were permeabilized with 0.2% Triton X-100 and incubated with cross-reactive rabbit anti-SARS-CoV-N IgG
(Sino Biological, Inc) for 1 h at room temperature before the addition of HRP-conjugated goat anti-rabbit IgG (H+L) antibody (Jackson
ImmunoResearch) and further incubated at room temperature. The foci were stained with KPL TrueBlue Peroxidase substrates (Ser-
aCare Life Sciences Inc.) and were counted with an EliSpot reader (Cellular Technology Ltd.).
Affinity determination by Bio-Layer Interferometry (BLI)
Affinity assays were performed on a ForteBio OctetRED 96 biolayer interferometry instrument (Molecular Devices ForteBio LLC,
Fremont, CA) at 25C with shaking at 1,000 rpm. To measure the affinity of Nbs with human Fc tag, anti-human Fc (AHC) biosen-
sors (cat.# 18-5060, Fortebio) were hydrated in water for 30 min prior to 60 s (sec) incubation in a kinetic buffer (PBS, 0.02% (v/v)
Tween-20, pH 7.0). Either Nb-Fc in cell supernatant or purified Nb-Fcs were loaded in a kinetic buffer for 200 s prior to baseline
equilibration for 200 s in a kinetic buffer. Association of SARS-CoV-2 RBD in a two-fold dilution series from 20 nM to 2.5 nM was
performed prior to dissociation for 180 s. To measure the affinity of Nbs without Fc tag, RBD protein was coupled to AR2G
biosensor (cat.# 18-5092, Fortebio) via BLI instrument according to the instructions of the amino coupling kit. Association of
Nbs in a serial dilution was performed prior to dissociation for 180 s. After each cycle, the biosensors were regenerated via 3 short
pulses of 5 s each of 100 mM pH 2.7 glycine-HCL followed by running buffer. The data were baseline subtracted before fitting
performed using a 1:1 binding model and the ForteBio data analysis software. KD, Ka and Kd values were evaluated with a global
fit applied to all data.
Epitope binning by BLI
The epitope binning assay was performed with AR2G biosensor (cat.# 18-5092, Fortebio) following the manufacturer’s protocol ‘in-
tandem assay’ as previously reported (Rogers et al., 2020). After loading the RBD protein, a saturating concentration of antibody or
Nbs (50 mg/ml) as the first antibody was added for 300 s following with the baseline step with 30 s immersion in 0.02% PBST. The
second competing concentration of antibody or Nb (50 mg/ml) was then added for 300 s tomeasure binding in the presence of the first
saturating antibody or Nb. GraphPad was used to illustrate the time-response course of two antibodies binding to RBD protein.
Pharmacokinetics of Nbs in vivo
Purified Nbs were injected intranasally (i.n.), intraperitoneally (i.p.) or intravascularly into BALB/c (Qing Long Shan Animal Center,
Nanjing, China) at a dose of 10-20 mg/kg. ELISA was used to measure the serum concentration of Nbs. The T1/2 of Nbs was
computed as ln (2)/k, where k is a rate constant expressed reciprocally of the x axis time units by the one phase decay equation
or plateau followed one phase decay in the GraphPad software.
Spatial distribution of Nbs in vivo
Nbswere labeled with far infrared dye YF750 SE (US EVERBRIGHT INC, YS0056) (named as Nbs-YF750). Purified Nbs-YF750were
injected i.n., i.p. or i.v. into nudemice (18-22 g, Qing Long Shan Animal Center, Nanjing, China) at a dose of 10-20mg/kg. Imageswere
observed at Ex:740 nm/Em:780 nm by NightOWL LB 983 (Berthold, Germany) at the indicated time point. Images were analyzed us-
ing Indigo imaging software Ver. A 01.19.01.
Evaluating the efficacy of Nbs in SARS-CoV-2 infected hACE2 mice
A total of 31 8-week-old male transgenic hACE2 mice (C57BL/6J) (cat.# T037630, GemPharmatech Co., Ltd., Nanjing, China) were
challenged with 1x 105 PFU SARS-CoV-2 (IVCAS 6.7512; Zhou et al., 2020) per mouse as previously reported (Ma et al., 2020) with
followingmodifications. Themice were split into seven groups (n = 3-5) for either prophylactic or therapeutic evaluation, as described
in Figure 5A. Mice without any challenge and treatment served as blank control (No SARS-CoV-2, n = 4). Mice challenged with SARS-
CoV-2 were taken as infection control (SARS-CoV-2, n = 5). 250 mg SNB02 (Y-Clone, China), an anti-SFTSV antibody constructed by
Nb fused with human Fc1 (Nb-Fc) (Wu et al., 2020a), was intranasally injected 1 h after infection and served as an isotype treated
control (Isotype). For the prophylactic group,micewere intranasally injectedwith Nb15-NbH-Nb15 at a dose of 250 mg/mouse (average
of 10 mg/kg) 24 h before infection (Nb15-NbH-Nb15 24h, n = 5). For the therapeutic group, mice were intranasally injected with N
Nb15-NbH-Nb15 at a dose of 250 mg/mouse (average of 10 mg/kg) 1 h or 24 h after infection (named as Nb15-NbH-Nb15 1h and
Nb15-NbH-Nb15 24 h, n = 5, respectively). As a comparison, Nb15-Fc at a dose of 250 mg/mouse (average of 10 mg/kg) was intrana-
sally injected 1 h after infection (Nb15-Fc 1 h). Body weight of every mouse was measured daily. Transgenic hACE2 mice typically
clear virus within five days after SARS-CoV-2 and viral RNA copies reached a peak at 3 dpi (Bao et al., 2020). Accordingly, the
mice were sacrificed at 3 days post infection (dpi), and the lungs were collected for viral load determination and tissue sections
for hematoxylin and eosin (H&E) and immunofluorescence staining.Cell Reports 37, 109869, October 19, 2021 e5
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Viral load was detected by quantitative real-time PCR (qRT-PCR) on RNA extracted from the supernatant of lung homogenates as
described previously (Cao et al., 2020). Briefly, lung homogenates were prepared by homogenizing perfused whole lung using an
electric homogenizer. The supernatant was collected, and total RNA was extracted. Each RNA sample was reverse transcribed to
50 mL cDNAwith RT-PCRPrime Script Kit (Takara). The cDNA (5 ml) was used in a 25 mL qRT-PCR reaction with the TaqManUniversal
PCR Master Mix (Life Technologies), a TaqMan probe (50-FAM CAGGTGGAACCTCATCAGGAGATGC MGB-30), and primers de-
signed to target the orf1ab gene of SARS-CoV-2 (50- GTGARATGGTCATGTGTGGCGG 30 and 50- CARATGTTAAASACACTATTAG
CATA30). The samples were run in triplicate on an ABI 7900 Real-Time System (Applied Biosystems, Thermo Fisher Scientific). The
following cycling conditions were used: 1 cycle of 50C for 2 min, 1 cycle of 95C for 10 min, and 40 cycles of 95C for 15 s and 58C
for 1 min. The virus titer was determined by comparison with a standard curve generated using RNA extracted from a serially diluted
reference viral stock. All experiments were performed in a Biosafety Level 3 facility.
Immunofluorescence staining of SARS-CoV-2-infected cells in tissues
Lung tissues were immersed in 10% neutral buffered formalin (cat.# Z2902, Sigma) for 24 h. After the formalin fixation, the tissues
were placed in 70% ethanol (Merck) and subsequently embedded with paraffin. Tissue sections (4-mm thick) were used for immu-
nofluorescence staining for SARS-CoV-2 detection using the Coronavirus nucleocapsid antibody (cat. 40143-MM05, Sino Biolog-
ical). Images were obtained by OLYMPUS IX73 using HCImage Live ( 3 64) software and analyzed by ImageJ (NIH).
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using GraphPad Prism 8.01 software (GraphPad) or OriginPro 8.5 software (OriginLab).
ANOVA or Mann-Whitney test was performed for group comparisons. p < 0.05 was considered as statistically significant with
mean ± SEM or mean ± SD. All of the statistical details of experiments can be found in the figure legends.e6 Cell Reports 37, 109869, October 19, 2021
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Supplemental Figure 1. Characterization of anti-sera specific for SARS-CoV-2. Related to Figure 6 
1. (A) The experimental schedule for immunization. The titer of anti-sera specific for SARS-CoV-2 S 7 
protein (B) and RBD protein (C) was evaluated one week after the immunization in alpaca receiving 8 
SARS-CoV-2 spike protein, respectively. The titer of the third anti-serum was indicated as blue line. 9 
The blue # indicates the anti-serum titer after the third immunization. 3rd anti-serum and 2nd anti-serum 10 
represent the anti-sera collected from alpaca one week after the 3rd and 2nd immunization. Blank serum 11 
represents the alpaca serum collected before immunization, which was taken as a negative control. (D) 12 
Neutralization potency of the immunized alpaca’s serum against pseudotyped SARS-CoV-2 was 13 
detected. ND50: half-maximal serum neutralization dilution titer. Titer and ND50 were indicated. Data of 14 





Supplemental Figure 2. The construction and biopanning of C9-Nb library. Related to Figure 1. 19 
(A) The table summary of C9-Nb library, wherein phage displayed Nb of PBMC from alpaca receiving 20 
three times immunization of SARS-CoV-2 S protein. (B) The binding of the phage library with S via 21 
phage ELISA. Lib is the phage library of C9-Nb; 1st, 2nd, and 3rd are the phage library after panning on 22 
1 round, 2 rounds, and 3 rounds of S protein enrichment, respectively. (C) Single clone of phages from 23 
the C9-Nb library after the second and third enrichment of SARS-CoV-2 S were analyzed by phage 24 





Supplemental Figure 3. Characterization of Nb-Fc. Related to Figure 1. (A) The diagram of Nb-Fc, 29 
constituted by Nb fusing with human Fc1. (B) 21 various Nb-Fcs binding with S and RBD protein 30 
identified by ELISA. Grey dot represents negative control. Green dots represent the specific binding 31 
with S protein. Blue dots represent the double binding with S and RBD protein. (C) Representative 32 
binding curve of Nb-Fcs with RBD tested by BLI. (D) The table summary of 21 Nb-Fcs binding with 33 
RBD tested by BLI. (E) The cell supernatants of 21 various Nb-Fcs were tested for neutralization 34 
against SARS-CoV-2 infection, the cell supernatant displaying outstanding neutralizing curve was 35 
labeled as the color-coded curve. Data of B represent as mean ± SEM. All experiments of B-E were 36 
repeated twice 37 
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 39 
Supplemental Figure 4. Characterization of purified Nb-Fcs. Related to Figure 1. (A) Purified Nb-40 
Fcs binding with RBD identified by ELISA. Data represent as mean ± SEM. (B) RBD protein under 41 
reducing condition (R) or non-reducing condition (NR) was detected by WB with Nb15-Fc, Nb22-Fc and 42 
Nb31-Fc. Kinetic binding curve of RBD with Nb15-Fc (C), Nb22-Fc (D) and Nb31-Fc (E), respectively. 43 





Supplemental Figure 5. Epitope analysis of Nb-Fcs by BLI. Related to Figure 1. RBD protein was 48 
coated on the sensor, Nb15-Fc (A), Nb22-Fc (B) or Nb31-Fc(C) as the first antibody was added to bind 49 
for 300 s following with the baseline step with 30 s immersion in 0.02% PBST. The second competing 50 
concentration of Nb (50 μg/ml) was then added for 300 sec to measure binding in the presence of the 51 






Supplemental Figure S6. Characterizing the potency of neutralization against authentic 57 
SARS-CoV-2 conferred by Nb-Fcs. Related to Figure 1. The neutralization potency of Nb15-Fc 58 
(A), Nb22-Fc (B), Nb31-Fc(C), SNB02 (isotype control antibody) (D) was detected based on 59 
authentic SARS-CoV-2 plaque reduction neutralization test. The raw data was depicted. (E) A table 60 
summary authentic SARS-CoV-2 neutralization potencies of Nb-Fcs.  61 
 7 
 62 
Supplemental Figure 7. Kinetic binding curve of Nb15-NbH-Nb15 with MSA. Related to Figure 5. 63 
Kinetic binding curve of Nb15-NbH-Nb15 at the concentration of 300 nM, 100nM, 33.3 nM,11.1nM, 64 
3.7nM and 1.2 nM with MSA by BLI. Binding curves are colored black, and fit of the data to a 1:1 65 






























Supplemental Table 1. Summary of CDR sequences of positive Nb clones. Related to Figure 1. 95 
ID CDR1 CDR2 CDR3
Nb1-Fc GNIFSIYT VTSGGST N-------------ARLFDPGY
Nb2-Fc GGTLASFA INIINRT AAHFVPPGSRLRDCLVNELYNY
Nb4-Fc GGTLASFA INIINRT AAHFVPPGSRLRGCLVNELYNY
Nb5-Fc GFTWNYHA ISSSGSTT AAPHSGSVCPR--WAEYYGVDH
Nb7-Fc GGTLASFA INIINRT AAHFVPPGSRLRGCLVNEAYNY
Nb9-Fc GGTLASFA INIINRT AAHFVPPGGRLRGCLVNDLYNY
Nb12-Fc GGTLASFA INIINRT AAHFVPPGSRLRGCLVNDLYNY
Nb13-Fc GGTLASFA ITNSGST N-----------------TFHY
Nb14-Fc GGTLASFA ISSSGGST TARPSLWAVVAGCPLDQNTYFS
Nb15-Fc GGTLASFA ISSSGST AG-VVHDVQAM--CVMNP-WGS
Nb19-Fc GGTLASFA INIINRT AAHFVPPGSRLRGCLVNDVYNY
Nb22-Fc GGTLASFA IDVINRA AAHFVPPGSRLRGCLVNELYNY
Nb24-Fc GGTLASFA INIINRT AAHFVPPESRLRGCLVNELYNY
Nb25-Fc GGTLASFA ITSRRDT YG------------QDVLGQIY
Nb27-Fc GGTLASFA ITSGGST TT------------AGSWQGDY
Nb28-Fc GGTLASFA INIINRT AAHFVPPESRLRGCLVNEAYNY
Nb29-Fc GGTLASFA ISSRSFT YG------------QDILGQIY
Nb30-Fc GGTLASFA INIINRT AAHFVPPGSRLRGCLVNELYNY
Nb31-Fc GGTLASFA INIINRP AAHFVPPGSRLGGCLVNELYNY
Nb33-Fc GGTLASFA INIINRT AAHFVPPGSRFRGCSVNELYNY
Nb34-Fc GGTLASFA INIINRP AAHFVPPGSRLGGCLVNELYNY


















Supplemental Table 2. Summary of Nbs inhibiting SARS-CoV-2 variants. Related to Figure 1. 113 
 114 
IC5 0 IC8 0 IC9 0 IC5 0 IC8 0 IC9 0 IC5 0 IC8 0 IC9 0 IC5 0 IC8 0 IC9 0
WT 0.0008±0.0001 0.0019±0.0004 0.0033±0.0012 0.0016±0.0001 0.0046±0.0012 0.0086±0.0033 0.0023±0.0004 0.0083±0.0019 0.0183±0.0059 0.0004±0 0.0012±0.0004 0.0018±0.0009
Q321L 0.0009±0.0004 0.0023±0.0007 0.0039±0.0008 0.0014±0.0003 0.0042±0.0009 0.0079±0.0019 0.002±0.0005 0.0065±0.0017 0.0133±0.0033 0.001±0.0001 0.0022±0.0004 0.0034±0.0009
V341I 0.0007±0.0002 0.0026±0.0005 0.0059±0.0019 0.0017±0.0005 0.0042±0.0007 0.007±0.001 0.0028±0.0004 0.0087±0.0024 0.0169±0.0058 0.0011±0.0001 0.0027±0.0009 0.0047±0.0022
A348T 0.001±0.0002 0.0023±0.0003 0.0036±0.0005 0.0019±0.0008 0.0046±0.0012 0.0076±0.0016 0.0029±0.0001 0.0088±0.0013 0.0176±0.0032 0.0008±0.0002 0.0014±0.0001 0.0019±0.0004
N354D 0.0008±0.0002 0.0022±0.0002 0.0041±0.001 0.0013±0.0003 0.0033±0.0005 0.0056±0.0012 0.0019±0.0001 0.0068±0.0018 0.0145±0.0051 0.0006±0.0002 0.0016±0.0006 0.0032±0.0013
S359N 0.0011±0.0001 0.0026±0.0003 0.0043±0.0006 0.0016±0.0003 0.0037±0.0005 0.0061±0.0008 0.002±0.0005 0.0064±0.0012 0.0129±0.0037 0.0008±0.0002 0.0017±0.0002 0.0025±0.0005
V367F 0.0007±0.0001 0.002±0.0002 0.0036±0.0004 0.0011±0.0003 0.0033±0.0003 0.0062±0.0004 0.0021±0.0006 0.0095±0.0017 0.0237±0.0022 0.0005±0 0.0013±0.0001 0.0026±0.0006
K378R 0.0007±0.0002 0.0024±0.0003 0.0046±0.0001 0.0012±0.0002 0.0028±0.0003 0.0045±0.0005 0.0013±0.0001 0.004±0.0004 0.0079±0.0017 0.0008±0.0002 0.002±0.0004 0.0033±0.0006
R408I 0.0007±0.0002 0.002±0.0007 0.0035±0.0016 0.001±0.0001 0.0027±0.0003 0.0047±0.0009 0.0014±0.0002 0.0038±0.001 0.0069±0.0026 0.0007±0.0001 0.0014±0.0002 0.002±0.0005
Q409E 0.0005±0.0001 0.0014±0 0.0026±0.0002 0.0009±0.0003 0.0022±0.0007 0.0036±0.0011 0.0009±0.0001 0.0029±0.0004 0.0057±0.0007 0.0007±0.0002 0.0014±0.0002 0.0021±0.0003
K458R 0.0009±0.0003 0.0025±0.0002 0.0047±0.0006 0.0013±0.0001 0.0041±0.0014 0.008±0.0036 0.0025±0.0003 0.0068±0.0013 0.0128±0.004 0.0008±0.0002 0.0018±0.0003 0.0029±0.0004
G476S 0.0006±0.0002 0.0015±0.0004 0.0025±0.0006 0.0013±0.0006 0.0034±0.0011 0.006±0.0013 0.0015±0.0001 0.0049±0.0008 0.0101±0.0023 0.0003±0.0001 0.0009±0.0002 0.0014±0.0003
V483A 0.0006±0.0001 0.0017±0.0005 0.0031±0.0011 0.0015±0.0003 0.0039±0.0008 0.0069±0.0026 0.0027±0.001 0.0093±0.0018 0.0206±0.0027 0.0005±0.0001 0.0013±0 0.0022±0.0002
Y508H 0.0005±0.0001 0.0023±0.0003 0.0053±0.001 0.0013±0.0002 0.0035±0.0007 0.006±0.0015 0.0018±0.0005 0.0068±0.0007 0.0157±0.0047 0.0008±0.0001 0.0019±0.0006 0.0033±0.0016
H519P 0.0008±0.0001 0.0023±0.0002 0.0041±0.0005 0.0011±0.0002 0.0033±0 0.006±0.0004 0.0014±0.0003 0.005±0.0004 0.0107±0.0032 0.0007±0.0002 0.0016±0.0001 0.0025±0.0002
D614G 0.0007±0.0001 0.002±0.0002 0.0035±0.0007 0.0012±0.0005 0.0033±0.0005 0.0059±0.0003 0.0015±0.0004 0.0039±0.001 0.0067±0.0016 0.0006±0.0001 0.0015±0.0005 0.0026±0.001
A435S N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.0007±0.0001 0.0015±0.0003 0.0024±0.0006
I472V N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.0006±0.0001 0.0014±0.0003 0.0023±0.0006
E484K N/A N/A N/A N/A N/A N/A N/A N/A N/A >1.000 >1.000 >1.000
N501Y N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.0007±0.0002 0.002±0.0005 0.0042±0.0013
Nb1 5-NbH-Nb1 5（mean±sd μg/ml）
Variants
Nb1 5-Fc （mean±sd μg/ml） Nb2 2-Fc （mean±sd μg/ml） Nb3 1-Fc（mean±sd μg/ml）
115 








Supplemental Table 3. Summary of RBD binding with Nb15s in different conditions. Related to 123 
Figure 5. 124 
Sample ID Condition Conc. (nM) Response KD (M) Ka(1/Ms) Kd(1/s) RMax Full R^2
WT 133.3 0.3806 <1.0E-12 3.44E+05 <1.0E-07 0.3687 0.9676
Aero 133.3 0.2139 9.92E-09 4.11E+04 4.08E-04 0.3277 0.9957
 37 oC 133.3 0.3756 <1.0E-12 1.89E+05 <1.0E-07 0.374 0.9948
50 oC 133.3 0.3903 5.78E-11 2.11E+05 1.22E-05 0.3849 0.996
 60 oC 133.3 0.4048 5.57E-10 1.91E+05 1.06E-04 0.402 0.9986
 70 oC 133.3 0.3775 2.52E-10 1.63E+05 4.10E-05 0.3801 0.9989
80  oC 133.3 0.3199 5.64E-09 5.85E+04 3.30E-04 0.4193 0.9994
90 oC 133.3 0.1078 1.02E-08 2.90E+04 2.95E-04 0.211 0.9978
WT 62.5 0.8028 <1.0E-12 6.98E+05 <1.0E-07 0.7814 0.9824
Aero 62.5 0.3398 2.79E-10 5.05E+04 1.41E-05 0.7387 0.999
 37 oC 62.5 0.8136 <1.0E-12 4.34E+05 <1.0E-07 0.804 0.9946
50 oC 62.5 0.853 <1.0E-12 4.11E+05 <1.0E-07 0.848 0.9976
 60 oC 62.5 0.7989 4.38E-11 4.11E+05 1.80E-05 0.7944 0.9979
 70 oC 62.5 0.6126 4.95E-09 8.87E+04 4.39E-04 0.956 0.9995
80  oC 62.5 0.2077 1.98E-08 4.16E+04 8.26E-04 0.557 0.9983
90 oC 62.5 0.1088 4.12E-08 2.76E+04 1.14E-03 0.4281 0.9978
WT 133.3 0.3769 <1.0E-12 6.20E+05 <1.0E-07 0.3637 0.8833
Aero 133.3 0.184 <1.0E-12 2.55E+04 <1.0E-07 0.3816 0.9946
 37 oC 133.3 0.3667 <1.0E-12 4.01E+05 <1.0E-07 0.3578 0.9563
50 oC 133.3 0.3588 <1.0E-12 3.96E+05 <1.0E-07 0.3507 0.9583
 60 oC 133.3 0.3715 <1.0E-12 3.49E+05 <1.0E-07 0.3635 0.9717
 70 oC 133.3 0.2294 <1.0E-12 2.78E+04 <1.0E-07 0.4508 0.9975
80  oC 133.3 0.2748 4.97E-10 4.53E+04 2.25E-05 0.4052 0.9994
90 oC 133.3 0.1294 4.87E-09 5.21E+04 2.54E-04 0.1778 0.9968
Nb1 5-Fc
Nb1 5-NbH-Nb1 5
3xNb1 5
125 
 126 
 127 
 128 
 129 
